Overview

Periarticular Bupivacaine + Meloxicam ER Solution Versus Standard Practice During Total Knee Arthroplasty

Status:
Enrolling by invitation

Trial end date:
2025-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare an FDA-approved medication for post-operative pain control (HTX-011) to the standard of care institutional practice for periarticular analgesia after primary total knee arthroplasty (weight based dosing of Ropivacaine, epinephrine and ketorolac diluted with saline). We are doing this research study to find out if this new medication provides superior pain control within 72 hours following surgery.

Phase:

Phase 4

Details

Lead Sponsor:

Mayo Clinic

Treatments:

Epinephrine
Ketorolac
Ropivacaine